NO2019038I1 - Risankizumab - Google Patents

Risankizumab

Info

Publication number
NO2019038I1
NO2019038I1 NO2019038C NO2019038C NO2019038I1 NO 2019038 I1 NO2019038 I1 NO 2019038I1 NO 2019038 C NO2019038 C NO 2019038C NO 2019038 C NO2019038 C NO 2019038C NO 2019038 I1 NO2019038 I1 NO 2019038I1
Authority
NO
Norway
Prior art keywords
risankizumab
Prior art date
Application number
NO2019038C
Other languages
English (en)
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US41015810P priority Critical
Priority to US41195310P priority
Priority to US41259410P priority
Priority to US201161448785P priority
Priority to PCT/US2011/058869 priority patent/WO2012061448A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44936573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2019038(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of NO2019038I1 publication Critical patent/NO2019038I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
NO2019038C 2010-11-04 2019-10-17 Risankizumab NO2019038I1 (no)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US41015810P true 2010-11-04 2010-11-04
US41195310P true 2010-11-10 2010-11-10
US41259410P true 2010-11-11 2010-11-11
US201161448785P true 2011-03-03 2011-03-03
PCT/US2011/058869 WO2012061448A1 (en) 2010-11-04 2011-11-02 Anti-il-23 antibodies

Publications (1)

Publication Number Publication Date
NO2019038I1 true NO2019038I1 (no) 2019-10-17

Family

ID=44936573

Family Applications (1)

Application Number Title Priority Date Filing Date
NO2019038C NO2019038I1 (no) 2010-11-04 2019-10-17 Risankizumab

Country Status (39)

Country Link
US (5) US8778346B2 (no)
EP (4) EP3456740A1 (no)
JP (3) JP6126532B2 (no)
KR (2) KR102049223B1 (no)
CN (2) CN103282382B (no)
AP (2) AP201306820A0 (no)
AR (1) AR083747A1 (no)
AU (3) AU2011323426B2 (no)
BR (1) BR112013011065A2 (no)
CA (2) CA3017116A1 (no)
CO (1) CO6801628A2 (no)
CY (1) CY1118014T1 (no)
DK (1) DK2635601T3 (no)
EA (2) EA201890548A1 (no)
EC (1) ECSP13012649A (no)
ES (1) ES2593754T3 (no)
GE (1) GEP201706733B (no)
HK (1) HK1247940A1 (no)
HR (1) HRP20161141T1 (no)
HU (2) HUE030916T2 (no)
IL (2) IL225648A (no)
LT (2) LT2635601T (no)
LU (1) LUC00132I2 (no)
MA (1) MA34641B1 (no)
ME (1) ME02499B (no)
MX (2) MX343858B (no)
MY (1) MY162791A (no)
NL (1) NL301013I2 (no)
NO (1) NO2019038I1 (no)
NZ (1) NZ610592A (no)
PE (1) PE20141162A1 (no)
PL (1) PL2635601T3 (no)
PT (1) PT2635601T (no)
RS (1) RS55161B1 (no)
SG (2) SG10201604605VA (no)
SI (1) SI2635601T1 (no)
TW (2) TWI653242B (no)
UY (1) UY33703A (no)
WO (1) WO2012061448A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
AP201306820A0 (en) 2010-11-04 2013-04-30 Boehringer Ingelheim Int Anti-IL-23 antibodies
AU2013256724A1 (en) * 2012-05-03 2014-10-30 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibodies
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合il-23之抗體
WO2014143540A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
AU2014238148A1 (en) 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
BR112017004169A2 (pt) 2014-09-03 2017-12-05 Boehringer Ingelheim Int composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
CA2972995A1 (en) * 2015-02-04 2016-08-11 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
WO2016168282A1 (en) 2015-04-14 2016-10-20 Boehringer Ingelheim International Gmbh Methods of treating diseases
EP3322436A4 (en) 2015-07-23 2019-03-27 Boehringer Ingelheim International GmbH COMPOUND TARGETING THE FACTOR OF ACTIVATION OF IL-23 AND LYMPHOCYTES B (BAFF) AND USES THEREOF
CN108290058A (zh) * 2015-09-17 2018-07-17 美国安进公司 使用il23途径生物标志物预测il23拮抗剂的临床应答
EP3350221A1 (en) * 2015-09-18 2018-07-25 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases
PE20181326A1 (es) * 2015-11-03 2018-08-20 Janssen Biotech Inc Anticuerpos que se unen especificamente a pd-1 y sus usos
JP6728392B2 (ja) 2016-04-15 2020-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 炎症性疾患の処置法
EP3677597A1 (en) 2016-10-14 2020-07-08 Boehringer Ingelheim International GmbH Methods of treating diseases
TW201946657A (zh) * 2018-03-30 2019-12-16 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
US20210277105A1 (en) 2018-07-13 2021-09-09 Astrazeneca Collaboration Ventures, Llc Treating ulcerative colitis with brazikumab
CN109810947B (zh) * 2019-01-18 2021-06-11 北京贝来生物科技有限公司 一种抑制Th17细胞活化的间充质干细胞及其制备方法和应用
WO2020212874A1 (en) * 2019-04-15 2020-10-22 Sun Pharma Global Fze Methods for treatment of subjects with psoriatic arthritis
US20210188961A1 (en) * 2019-12-20 2021-06-24 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
CN111956606B (zh) * 2020-08-31 2021-05-14 江苏荃信生物医药有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
JPS6023084B2 (no) 1979-07-11 1985-06-05 Ajinomoto Kk
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
PE20000183A1 (es) 1997-07-25 2000-03-11 Schering Corp Citoquinas de mamiferos y reactivos relacionados
AU2661199A (en) 1998-02-06 1999-08-23 Schering Corporation Mammalian receptor proteins; related reagents and methods
AU3170199A (en) 1998-04-14 1999-11-08 Chugai Research Institute For Molecular Medicine, Inc. Novel cytokine-like protein
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
JP4505166B2 (ja) 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−12p40およびインターロイキンb30、その組成物、抗体、薬学的組成物における使用
US6756481B2 (en) 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
JPWO2003034818A1 (ja) 2001-10-24 2005-02-10 中外製薬株式会社 Sgrf遺伝子改変非ヒト動物
CN1292655C (zh) 2001-11-08 2007-01-03 蛋白质设计实验室股份有限公司 IgG抗体稳定的液态药物制剂
JP5477998B2 (ja) 2002-10-30 2014-04-23 ジェネンテック, インコーポレイテッド Il−17産生の阻害
US7332156B2 (en) 2002-12-23 2008-02-19 Schering Corporation Methods of treating wounds using IL-23
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
DE602004022781D1 (de) 2003-03-10 2009-10-08 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
WO2005005612A2 (en) 2003-07-01 2005-01-20 University Of Virginia Patent Foundation Tag-1 and tag-2 proteins and uses thereof
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DE602004028037D1 (de) 2003-11-04 2010-08-19 Novartis Vaccines & Diagnostic Verfahren zur behandlung von krebs mit expression des cd40-antigens
ES2346978T3 (es) 2003-11-04 2010-10-22 Novartis Vaccines And Diagnostics, Inc. Uso de anticuerpos monoclonantes anti-cd40 antagonistas para el tratamiento del mieloma multiple.
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
JP4903061B2 (ja) 2004-02-17 2012-03-21 シェーリング コーポレイション Il−23活性を調節する方法;関連する試薬
WO2005108616A1 (en) 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
JP2008537874A (ja) * 2004-09-27 2008-10-02 セントカー・インコーポレーテツド sRAGEミメティボディ、組成物、方法および使用
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP1853707A2 (en) 2004-12-20 2007-11-14 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
EP1896073B1 (en) 2005-06-30 2013-03-06 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
EP1910414A4 (en) 2005-06-30 2009-02-11 Archemix Corp POLYNUCLEOTIDES AND POLYPEPTIDES OF THE CYTOKINE IL-12 FAMILY
MX2008002179A (es) * 2005-08-25 2008-04-22 Lilly Co Eli Anticuerpos anti-il-23.
CN101248088A (zh) * 2005-08-25 2008-08-20 伊莱利利公司 抗il-23抗体
DK1931710T3 (en) 2005-08-31 2017-04-03 Merck Sharp & Dohme Constructed anti-il-23 antibodies
CA2621086A1 (en) 2005-09-01 2007-03-08 Schering Corporation Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
AU2006330410A1 (en) 2005-12-28 2007-07-05 Centocor, Inc. Markers and methods for assessing and treating psoriasis and related disorders
DK2548577T3 (en) 2005-12-29 2017-03-13 Janssen Biotech Inc HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US20080311043A1 (en) 2006-06-08 2008-12-18 Hoffman Rebecca S Uses and compositions for treatment of psoriatic arthritis
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
JP2009541338A (ja) 2006-06-19 2009-11-26 ワイス Il−22およびil−17の調節方法
EP2114451A2 (en) 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Anti-il-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
US20080200655A1 (en) 2007-02-16 2008-08-21 Wyeth Protein Formulations Containing Sorbitol
CA2678863A1 (en) 2007-02-23 2008-08-28 Schering Corporation Engineered anti-il-23p19 antibodies
NZ579158A (en) 2007-02-23 2012-01-12 Schering Corp Engineered anti-il-23p19 antibodies
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
CA2698357C (en) 2007-09-04 2017-06-06 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Deletions in domain ii of pseudomonas exotoxin a that reduce non-specific toxicity
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2212442A1 (en) 2007-10-26 2010-08-04 Galderma Research & Development Non-invasive method to perform skin inflammatory disease pharmaco-genomic studies and diagnosis method thereof
CA2607771A1 (en) 2007-11-01 2009-05-01 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Humanized anti-venezuelan equine encephalitis virus recombinant antibody
KR20190045414A (ko) 2007-11-30 2019-05-02 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US9724410B2 (en) 2009-11-24 2017-08-08 Alderbio Holdings Llc Anti-IL-6 antibodies or fragments thereof to treat or inhibit cachexia, associated with chemotherapy toxicity
AU2009281713B9 (en) 2008-08-14 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Anti-IL-12/IL-23 antibodies
CN102202655B (zh) 2008-08-27 2013-06-19 默沙东公司 基因工程抗IL-23p19抗体的冻干制剂
US8257397B2 (en) 2009-12-02 2012-09-04 Spartek Medical, Inc. Low profile spinal prosthesis incorporating a bone anchor having a deflectable post and a compound spinal rod
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
EP2414546A4 (en) 2009-04-02 2013-03-13 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF CHRONIC INFLAMMATORY INTESTINAL DISEASES AND COLON CANCER
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US8927693B2 (en) 2010-02-18 2015-01-06 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind IL-23
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
US9956165B2 (en) 2010-03-01 2018-05-01 Cytodyn Inc. Concentrated protein formulations and uses thereof
KR101913868B1 (ko) 2010-06-15 2018-12-28 셀진 코포레이션 건선의 치료를 위한 바이오마커
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
US9127057B2 (en) 2010-07-20 2015-09-08 Teva Pharmaceuticals Ausralia Pty Ltd Anti-IL-23 heterodimer specific antibodies
GB201013975D0 (en) 2010-08-20 2010-10-06 Imp Innovations Ltd Method of treating desease
EP2640745B1 (en) 2010-09-10 2018-11-07 MedImmune Limited Bivalent and bispecific anti-il6/anti-il23 antibodies
AP201306820A0 (en) 2010-11-04 2013-04-30 Boehringer Ingelheim Int Anti-IL-23 antibodies
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
TW201309330A (zh) 2011-01-28 2013-03-01 Abbott Lab 包含糖基化抗體之組合物及其用途
WO2012104402A1 (en) 2011-02-04 2012-08-09 Ab Science Treatment of severe persitent asthma with masitinib
AU2013256724A1 (en) 2012-05-03 2014-10-30 Boehringer Ingelheim International Gmbh Anti-IL-23p19 antibodies
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
AU2014238148A1 (en) 2013-03-15 2015-10-08 Amgen Inc. Methods for treating psoriasis using an anti-IL-23 antibody
WO2014143540A1 (en) 2013-03-15 2014-09-18 Amgen Inc. Methods for treating crohn's disease using an anti-il23 antibody
KR20140119396A (ko) 2013-03-29 2014-10-10 삼성전자주식회사 단백질 약물의 액상 제형
BR112017004169A2 (pt) 2014-09-03 2017-12-05 Boehringer Ingelheim Int composto direcionado à il-23a e ao tnf-alfa e usos do mesmo
CA2972995A1 (en) 2015-02-04 2016-08-11 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
EP3322436A4 (en) 2015-07-23 2019-03-27 Boehringer Ingelheim International GmbH COMPOUND TARGETING THE FACTOR OF ACTIVATION OF IL-23 AND LYMPHOCYTES B (BAFF) AND USES THEREOF
EP3350221A1 (en) 2015-09-18 2018-07-25 Boehringer Ingelheim International GmbH Methods of treating inflammatory diseases

Also Published As

Publication number Publication date
BR112013011065A2 (pt) 2018-09-25
EA201890548A1 (ru) 2018-07-31
JP2019054809A (ja) 2019-04-11
LTC2635601I2 (lt) 2021-07-12
PT2635601T (pt) 2016-09-27
US9441036B2 (en) 2016-09-13
JP6445596B2 (ja) 2018-12-26
US20190144534A1 (en) 2019-05-16
WO2012061448A1 (en) 2012-05-10
NZ610592A (en) 2015-03-27
HUS1900048I1 (hu) 2019-11-28
IL225648D0 (en) 2013-06-27
TW201641516A (zh) 2016-12-01
MX362039B (es) 2019-01-07
AU2016273970B2 (en) 2018-06-28
ME02499B (me) 2017-02-20
RS55161B1 (sr) 2017-01-31
EP3115375A1 (en) 2017-01-11
AR083747A1 (es) 2013-03-20
US8778346B2 (en) 2014-07-15
JP2017079785A (ja) 2017-05-18
JP2014500009A (ja) 2014-01-09
GEP201706733B (en) 2017-09-25
HUE030916T2 (en) 2017-06-28
ECSP13012649A (es) 2013-07-31
AU2018236692B2 (en) 2020-07-02
EA030436B1 (ru) 2018-08-31
CA2816950A1 (en) 2012-05-10
EP3456740A1 (en) 2019-03-20
JP6758361B2 (ja) 2020-09-23
LUC00132I2 (no) 2020-07-16
TWI653242B (zh) 2019-03-11
US20160333091A1 (en) 2016-11-17
AU2011323426B2 (en) 2016-09-29
EP3281954A1 (en) 2018-02-14
PL2635601T3 (pl) 2017-02-28
MX2013005015A (es) 2013-08-08
IL244335A (en) 2017-11-30
CA2816950C (en) 2018-11-27
CN103282382B (zh) 2017-11-03
IL244335D0 (en) 2016-04-21
LTPA2019518I1 (lt) 2019-11-11
AU2016273970A1 (en) 2017-01-12
JP6126532B2 (ja) 2017-05-10
US20210198355A1 (en) 2021-07-01
KR20180137588A (ko) 2018-12-27
EA201300530A1 (ru) 2013-12-30
US20120282269A1 (en) 2012-11-08
KR101931591B1 (ko) 2018-12-24
SG10201604605VA (en) 2016-07-28
AP2013006820A0 (en) 2013-04-30
MY162791A (en) 2017-07-14
NL301013I2 (nl) 2020-01-09
TW201307386A (zh) 2013-02-16
US10202448B2 (en) 2019-02-12
PE20141162A1 (es) 2014-09-18
MA34641B1 (fr) 2013-11-02
HK1247940A1 (zh) 2018-10-05
MX343858B (es) 2016-11-25
IL225648A (en) 2016-04-21
SI2635601T1 (sl) 2017-01-31
LT2635601T (lt) 2016-10-10
DK2635601T3 (en) 2016-09-19
EP2635601B1 (en) 2016-07-20
AP201306820A0 (en) 2013-04-30
AU2011323426A1 (en) 2013-06-06
AU2018236692A1 (en) 2018-10-11
CO6801628A2 (es) 2013-11-29
UY33703A (es) 2012-06-29
KR102049223B1 (ko) 2019-11-28
CY1118014T1 (el) 2017-05-17
EP2635601A1 (en) 2013-09-11
HRP20161141T1 (hr) 2016-12-02
CN107522784B (zh) 2021-07-02
US20140363444A1 (en) 2014-12-11
NL301013I1 (no) 2019-10-22
CN103282382A (zh) 2013-09-04
ES2593754T3 (es) 2016-12-13
AP3953A (en) 2016-12-22
CN107522784A (zh) 2017-12-29
LUC00132I1 (no) 2019-10-16
SG190006A1 (en) 2013-06-28
CA3017116A1 (en) 2012-05-10
TWI545133B (zh) 2016-08-11
KR20130139975A (ko) 2013-12-23

Similar Documents

Publication Publication Date Title
NL300967I1 (nl) tisagenlecleucel
NL300986I2 (nl) lanadelumab
NL300940I2 (nl) emicizumab
NL300979I2 (nl) galcanezumab
NO2019038I1 (no) Risankizumab
NO2018039I1 (no) Rukaparibkamsylat
CR20130111A (es) Triazina-oxidiazoles
DK3225404T3 (da) Fluidpatron
BR112012028556A2 (pt) Indóis
DE10170954T8 (de) Mikrowellendruckgarer
DE102011100241A8 (de) Nitridhalbleiterbauteil
DE102011117046A8 (de) Doppelkupplungswindungsgetriebe
DE112011102080A5 (de) Kupplungszentralausrücker
DE112011104226A5 (de) Käfigmutter
DE102011002623A8 (de) Ventilsteuerzeitversteller
FI20105508A (fi) Varvasortoosisukka
CO6801789A2 (es) N-hetarilmetil pirazolilcarboxamidas
NO20111033A1 (no) Stromningsreguleringsapparat
DE112011101796A5 (de) Redoxakkumulatoranlage
DE112010005518A5 (de) Dichtungsmanchette
DE102010038420A8 (de) Reinigungungsvorrichtung
DK2596072T3 (da) Bor-forbindelses-suspension
DE102010035554B8 (de) Fußtüröffner
FI20100349A (fi) Porasovitelma
FR2959386B1 (fr) Pretailleuse